Please login to the form below

Not currently logged in
Email:
Password:

FDA advisors support anal cancer vaccine

Outside advisors to the US Food and Drug Administration have recommended the approval of Merck's Gardasil in preventing anal cancer

A panel of outside advisors to the US Food and Drug Administration (FDA) have recommended that the agency approve Merck's marketed cervical cancer vaccine Gardasil for the new indication of preventing anal cancer, which is caused by human papillomavirus (HPV) in approximately 90 per cent of cases. 

The Vaccines and Related Biological Products Advisory Committee voted that the data supplied by Merck support the safety and efficacy of Gardasil (human papillomavirus quadrivalent Types 6, 11, 16, and 18 vaccine, recombinant) for the prevention of anal cancer and anal intraepithelial neoplasia in men and women between nine and 26 years of age.

The HPV vaccine is already approved in the US  for female patients between the ages of nine and 26 to prevent cervical, vulvar and vaginal cancers, as well as genital warts and precancerous or dysplastic lesions.

Merck filed a supplemental Biologics Licence Application seeking approval for the anal cancer indication early this year.  Although the FDA is not required to follow its advisory committees' advice in evaluating marketing applications, it frequently does so.

Merck's supplementary application was based on the results of a study of men who have sex with men because of the high risk of anal infection in the population. However, the company is seeking approval in both men and women based on the research because the disease is similar in both sexes.

19th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....
segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....

Infographics